Market closed
Applied Therapeutics/$APLT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Applied Therapeutics
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Ticker
$APLT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
35
Website
APLT Metrics
BasicAdvanced
$47M
-
-$0.76
1.89
-
Price and volume
Market cap
$47M
Beta
1.89
52-week high
$9.85
52-week low
$0.30
Average daily volume
2M
Financial strength
Current ratio
3.064
Quick ratio
2.909
Long term debt to equity
4.191
Total debt to equity
4.903
Management effectiveness
Return on assets (TTM)
-92.12%
Return on equity (TTM)
-529.97%
Valuation
Price to revenue (TTM)
102.147
Price to book
0.8
Price to tangible book (TTM)
0.8
Price to free cash flow (TTM)
-0.551
Growth
Revenue change (TTM)
-95.45%
Earnings per share change (TTM)
-46.54%
3-year earnings per share growth (CAGR)
-43.10%
What the Analysts think about APLT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Applied Therapeutics stock.
APLT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
APLT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
APLT News
AllArticlesVideos
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
GlobeNewsWire·3 weeks ago
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
GlobeNewsWire·1 month ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. Lawsuit - APLT
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Applied Therapeutics stock?
Applied Therapeutics (APLT) has a market cap of $47M as of April 20, 2025.
What is the P/E ratio for Applied Therapeutics stock?
The price to earnings (P/E) ratio for Applied Therapeutics (APLT) stock is 0 as of April 20, 2025.
Does Applied Therapeutics stock pay dividends?
No, Applied Therapeutics (APLT) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next Applied Therapeutics dividend payment date?
Applied Therapeutics (APLT) stock does not pay dividends to its shareholders.
What is the beta indicator for Applied Therapeutics?
Applied Therapeutics (APLT) has a beta rating of 1.89. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.